The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
Open accessAbstract
Purpose: Preexisting antiviral antibodies in cancer patients can quickly neutralize oncolytic measles virus (MV) and decrease its antitumor potency. In contrast to “naked” viruses, cell-associated viruses are protected from antibody neutralization. Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used. Experimental Design: Antimeasles antibodies titers in ovarian cancer patients were determined. The protection of MV by MSC from antimeasles antibodies, the in vivo biodistribution profiles, and tumor infiltration capability of MSC were determined. Measles-naïve or immune tumor–bearing mice were treated with naked virus or MSC-associated virus and mice survivals were compared. Results: MSC transferred MV infection to target cells via cell-to-cell heterofusion and induced syncytia formation in the presence of high titers of antimeasles antibody, at levels that completely inactivated naked virus. Athymic mice bearing i.p. human SKOV3ip.1 ovarian tumor xenografts passively immunized with measles-immune human serum were treated with saline, naked MV, or MV-infected MSC. Bioluminescent and fluorescent imaging data indicated that i.p. administered MSC localized to peritoneal tumors, infiltrated into the tumor parenchyma, and transferred virus infection to tumors in measles naïve and passively immunized mice. Survival of the measles-immune mice was significantly enhanced by treatment with MV-infected MSC. In contrast, survivals of passively immunized mice were not prolonged by treatment with naked virus or uninfected MSC. Conclusions: MSC should be used as carriers of MV for intraperitoneal virotherapy in measles-immune ovarian cancer patients. (Clin Cancer Res 2009;15(23):7246–55)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells
Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008) · Gene Therapy · doi:10.1038/gt.2008.39 · Cited by 579
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe
Kidd, S., Spaeth, E., Klopp, A., Andreeff, M., Hall, B., & Marini, F. (2008) · Cytotherapy · doi:10.1080/14653240802486517 · Cited by 128
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationTherapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 584
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Metadata
- Authors
- Mader, E. K., Maeyama, Y., Lin, Y., Butler, G. W., Russell, H. M., Galanis, E., Russell, S. J., Dietz, A. B., & Peng, K.-W.
- Venue
- Clinical Cancer Research
- Published
- 2009-11-30
- Volume
- 15
- Issue
- 23
- Pages
- 7246-7255
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2137322846
- Cited by
- 204
- References
- 4
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1292
- The paper
- Mader, E. K., Maeyama, Y., Lin, Y., Butler, G. W., Russell, H. M., Galanis, E., Russell, S. J., Dietz, A. B., & Peng, K.-W. (2009). Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.